Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: Results from a randomized study

The immunogenicity of the human papillomavirus (HPV)-16/18 AS 04-adjuvanted vaccine (Cervarix(®), GlaxoSmithKline Biologicals) administered according to its licensed vaccination schedule (3-dose, 3D) and formulation (20 µg of each HPV antigen; 20/20F) has previously been demonstrated. This partially...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Romanowski, Barbara, Schwarz, Tino F, Ferguson, Linda M, Peters, Klaus, Dionne, Marc, Schulze, Karin, Ramjattan, Brian, Hillemanns, Peter, Catteau, Grégory, Dobbelaere, Kurt, Schuind, Anne, Descamps, Dominique
Formato: Artigo
Idioma:Inglês
Publicado: Landes Bioscience 2011
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3338934/
https://ncbi.nlm.nih.gov/pubmed/22048171
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.7.12.18322
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares